172 related articles for article (PubMed ID: 37925531)
21. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
22. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
[TBL] [Abstract][Full Text] [Related]
23. Busulfan-Based and Treosulfan-Based Myeloablative Conditioning for Allogeneic Transplantation in Children with Thalassemia Major: a Single-Center Experience From Southern Turkey.
Aygüneş U; Karagun BS; Ay Tuncel D; Sasmaz HI; Antmen B
Exp Clin Transplant; 2023 Nov; 21(11):883-892. PubMed ID: 38140932
[TBL] [Abstract][Full Text] [Related]
24. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Huttunen P; Taskinen M; Vettenranta K
Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Bernardo ME; Piras E; Vacca A; Giorgiani G; Zecca M; Bertaina A; Pagliara D; Contoli B; Pinto RM; Caocci G; Mastronuzzi A; La Nasa G; Locatelli F
Blood; 2012 Jul; 120(2):473-6. PubMed ID: 22645178
[TBL] [Abstract][Full Text] [Related]
26. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Baronciani D; Depau C; Targhetta C; Derudas D; Culurgioni F; Tandurella I; Latte G; Palmas A; Angelucci E
Hematol Oncol; 2016 Mar; 34(1):17-21. PubMed ID: 25626861
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.
Burroughs LM; Shimamura A; Talano JA; Domm JA; Baker KK; Delaney C; Frangoul H; Margolis DA; Baker KS; Nemecek ER; Geddis AE; Sandmaier BM; Deeg HJ; Storb R; Woolfrey AE
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1669-1677. PubMed ID: 28602958
[TBL] [Abstract][Full Text] [Related]
29. Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
Ussowicz M
Drugs Today (Barc); 2020 Jun; 56(6):389-403. PubMed ID: 32525137
[TBL] [Abstract][Full Text] [Related]
30. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Galán V; Beléndez C; Echecopar C; Estival P; Sissini L; Olivas R; Bueno D; Molina B; Fuentes C; Regueiro A; Benítez I; Plaza M; Margarit A; Rifón J; Pascual A; Palomo P; Urtasun A; Fuster JL; Díaz de Heredia C; Fernández Navarro JM; González-Vicent M; Ruz B; Pérez-Martínez A
Transplant Cell Ther; 2023 Nov; 29(11):702.e1-702.e11. PubMed ID: 37595686
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
33. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
Schmidt-Hieber M; Blau IW; Trenschel R; Andreesen R; Stuhler G; Einsele H; Kanz L; Keilholz U; Marinets O; Beelen DW; Fauser AA; Volin L; Ruutu T; Uharek L; Fietz T; Knauf W; Hopfenmüller W; Thiel E; Freund M; Casper J
Bone Marrow Transplant; 2007 Apr; 39(7):389-96. PubMed ID: 17310135
[TBL] [Abstract][Full Text] [Related]
34. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269
[TBL] [Abstract][Full Text] [Related]
35. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Casper J; Knauf W; Kiefer T; Wolff D; Steiner B; Hammer U; Wegener R; Kleine HD; Wilhelm S; Knopp A; Hartung G; Dölken G; Freund M
Blood; 2004 Jan; 103(2):725-31. PubMed ID: 12947008
[TBL] [Abstract][Full Text] [Related]
36. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Baronciani D; Rambaldi A; Iori AP; Di Bartolomeo P; Pilo F; Pettinau M; Depau C; Mico C; Santarone S; Angelucci E
Am J Hematol; 2008 Sep; 83(9):717-20. PubMed ID: 18626885
[TBL] [Abstract][Full Text] [Related]
37. Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Deeg HJ; Stevens EA; Salit RB; Ermoian RP; Fang M; Gyurkocza B; Sorror ML; Fatobene G; Baumgart J; Burroughs LM; Delaney C; Doney K; Egan DN; Flowers MED; Milano F; Radich JP; Scott BL; Sickle EJ; Wood BL; Yeung C; Storer BE
Biol Blood Marrow Transplant; 2018 May; 24(5):956-963. PubMed ID: 29274396
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
[TBL] [Abstract][Full Text] [Related]
39. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Slatter MA; Rao K; Abd Hamid IJ; Nademi Z; Chiesa R; Elfeky R; Pearce MS; Amrolia P; Worth A; Flood T; Abinun M; Hambleton S; Qasim W; Gaspar HB; Cant AJ; Gennery AR; Veys P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):529-536. PubMed ID: 29155317
[TBL] [Abstract][Full Text] [Related]
40. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
